SIBIONICS Showcases GS3 at Melbourne Congress
Analysis based on 7 articles · First reported Jul 20, 2026 · Last updated Aug 31, 2026
The showcase may increase Sibionics' visibility and credibility in the diabetes technology market, potentially boosting adoption of its GS3 sensor. This could intensify competition in the CGM market, affecting established players like Dexcom and Abbott, though the immediate market impact is likely limited as this is a product demonstration at a medical congress.
Sibionics showcased its GS3 continuous glucose monitoring (CGM) sensor and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress held in Melbourne from 18-21 August. The company presented its technology at Booth #1, hosted a scientific symposium titled 'Beyond Glucose: The Integrated Future of CGM, CKM, and AI in Diabetes' jointly with Air Liquide Healthcare, and conducted on-site interviews with Credentialled Diabetes Educators (CDEs). The GS3 sensor is factory-calibrated, lasts 14 days, and has a 2.9 mm profile. Sibionics highlighted its background in brain-computer interfaces, including a retinal prosthesis, as the engineering foundation for its CGM technology. The symposium featured presentations by Professor Sofianos Andrikopoulos (Group CEO of the Australian Diabetes Society), Professor David O Neal (University of Melbourne), Associate Professor Shannon Lin (University of Technology Sydney), and Professor Li Qiang (First Affiliated Hospital of Xi an Jiaotong University). CDEs provided positive feedback on the sensor's comfort and ease of use, and noted potential in AI-supported spike detection and meal logging. Sibionics plans to integrate its sensing platform with continuous ketone monitoring, insulin delivery, and AI to create a comprehensive diabetes management ecosystem.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard